Literature DB >> 8382459

Guidelines for counseling persons infected with human T-lymphotropic virus type I (HTLV-I) and type II (HTLV-II). Centers for Disease Control and Prevention and the U.S.P.H.S. Working Group.

.   

Abstract

The human T-lymphotropic viruses type I (HTLV-I) and type II (HTLV-II) are closely related but distinct retroviruses that can infect humans. They differ from the human immunodeficiency viruses that cause the acquired immunodeficiency syndrome. Screening of the U.S. blood supply for HTLV-I/II, which began in 1988, identifies HTLV-I- and HTLV-II-infected persons who need to be counseled regarding their infections. This paper summarizes current information about the HTLV viruses and presents guidelines developed by the Centers for Disease Control and a United States Public Health Service working group for counseling persons infected with HTLV-I and HTLV-II.

Entities:  

Mesh:

Year:  1993        PMID: 8382459     DOI: 10.7326/0003-4819-118-6-199303150-00009

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  18 in total

1.  Significance of indeterminate reactivity to human T-cell lymphotropic virus in western blot analysis of individuals at risk.

Authors:  F J Medrano; V Soriano; E J Calderón; C Rey; M Gutiérrez; R Bravo; M Leal; J González-Lahoz; E Lissen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-03       Impact factor: 3.267

2.  Impact of initial screening for human T-cell lymphotropic virus (HTLV) antibodies on efficiency of HTLV Western blotting.

Authors:  H E Prince; M Gross
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

Review 3.  Transmission of tropical and geographically restricted infections during solid-organ transplantation.

Authors:  P Martín-Dávila; J Fortún; R López-Vélez; F Norman; M Montes de Oca; P Zamarrón; M I González; A Moreno; T Pumarola; G Garrido; A Candela; S Moreno
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

Review 4.  Serodiagnosis for tumor viruses.

Authors:  Brian J Morrison; Nazzarena Labo; Wendell J Miley; Denise Whitby
Journal:  Semin Oncol       Date:  2014-12-31       Impact factor: 4.929

Review 5.  Transfusion-Transmitted Infections: an Update on Product Screening, Diagnostic Techniques, and the Path Ahead.

Authors:  Christina L Dean; Jenna Wade; John D Roback
Journal:  J Clin Microbiol       Date:  2018-06-25       Impact factor: 5.948

6.  Cervical shedding of human T cell lymphotropic virus type I is associated with cervicitis.

Authors:  Joseph R Zunt; Charlene S Dezzutti; Silvia M Montano; Katherine K Thomas; Jorge O V Alarcón; Eberth Quijano; Barry N Courtois; Jorge L Sánchez; Pablo Campos; Eduardo Gotuzzo; Patricia C Guenthner; Renu B Lal; King K Holmes
Journal:  J Infect Dis       Date:  2002-11-06       Impact factor: 5.226

7.  Human T cell lymphotropic virus type 1 infection among U.S. thalassemia patients.

Authors:  William M Switzer; Anupama Shankar; Sean R Trimble; Alexis A Thompson; Patricia J Giardina; Alan R Cohen; Thomas D Coates; Elliott Vichinsky; Ellis J Neufeld; Jeanne M Boudreaux; Walid Heneine
Journal:  AIDS Res Hum Retroviruses       Date:  2013-03-12       Impact factor: 2.205

8.  Human T-cell leukemia virus type II infection among high risk groups and its influence on HIV-1 disease progression.

Authors:  M Giacomo; E G Franco; C Claudio; C Carlo; D A Anna; D Anna; F Franco
Journal:  Eur J Epidemiol       Date:  1995-10       Impact factor: 8.082

9.  Immune recognition of genetically diverse simian T-cell lymphotropic virus type I isolates.

Authors:  A Lazo; R T Bailer; J R Blakeslee; R Yanagihara; V C Stevens; L Kramer; M D Lairmore
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

10.  The cutaneous T cell lymphoma, mycosis fungoides, is a human T cell lymphotropic virus-associated disease. A study of 50 patients.

Authors:  B A Pancake; D Zucker-Franklin; E E Coutavas
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.